<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Fixation of new seven Standard Input Output Norms (SIONs) at SION No. No. A-3708, A-3709, A-3710, A-3711, A-3712, A-3713 &amp; A-3714 under &quot;Chemical and Allied Product&quot; (Product Code-&#039;A&#039;)</title>
    <link>https://www.taxtmi.com/circulars?id=70660</link>
    <description>Seven new Standard Input Output Norms are notified under the Chemical and Allied Products product group for specified pharmaceutical and chemical export products. The norms prescribe permissible import inputs and quantities, including inputs for Theophylline, Liraglutide injection, Lumefantrine, specified Meropenem formulations, and ophthalmic solution. Bulk-drug content in ophthalmic solution must conform to the Drug Manufacturing Licence. Regional Authorities may grant Advance Authorisations directly in eligible cases without individual reference to the Norms Committee.</description>
    <language>en-us</language>
    <pubDate>Mon, 03 Aug 2026 00:00:00 +0530</pubDate>
    <lastBuildDate>Mon, 03 Aug 2026 18:26:59 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=915060" rel="self" type="application/rss+xml"/>
    <item>
      <title>Fixation of new seven Standard Input Output Norms (SIONs) at SION No. No. A-3708, A-3709, A-3710, A-3711, A-3712, A-3713 &amp; A-3714 under &quot;Chemical and Allied Product&quot; (Product Code-&#039;A&#039;)</title>
      <link>https://www.taxtmi.com/circulars?id=70660</link>
      <description>Seven new Standard Input Output Norms are notified under the Chemical and Allied Products product group for specified pharmaceutical and chemical export products. The norms prescribe permissible import inputs and quantities, including inputs for Theophylline, Liraglutide injection, Lumefantrine, specified Meropenem formulations, and ophthalmic solution. Bulk-drug content in ophthalmic solution must conform to the Drug Manufacturing Licence. Regional Authorities may grant Advance Authorisations directly in eligible cases without individual reference to the Norms Committee.</description>
      <category>Circulars</category>
      <law>DGFT</law>
      <pubDate>Mon, 03 Aug 2026 00:00:00 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/circulars?id=70660</guid>
    </item>
  </channel>
</rss>